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Background /Aims: Myofibroblast apoptosis promotes the resolution of liver 
fibrosis.  However, retaining macrophages may enhance reversal. The effects of 
specifically stimulating myofibroblast apoptosis in vivo was assessed.   Methods: 
An antibody (C1-3) to an extracellular domain of a myofibroblast membrane 
protein was injected as a fluorescent- or gliotoxin-conjugate into mice with liver 
fibrosis.  Results: C1-3 specifically targeted α-smooth muscle actin positive liver 
myofibroblasts within scar regions of the liver in vivo and did not co-localise with 
liver monocytes/macrophages.  Injection of free gliotoxin stimulated a two-fold 
increase in non-parenchymal cell apoptosis and depleted liver myofibroblasts by 
30% and monocytes/macrophages by 50% but had no effect on fibrosis severity 
in the sustained injury model employed.  In contrast, C1-3-targeted gliotoxin 
stimulated a five-fold increase in non-parenchymal cell apoptosis, depleted liver 
myofibroblasts by 60%, did not affect the number of monocytes/macrophages 
and significantly reduced fibrosis severity.  Fibrosis reduction was associated 
with increased metalloproteinase-13 levels.  Conclusions:  These data 
demonstrate that specific targeting of liver myofibroblast apoptosis is the most 
effective anti-fibrogenic therapy, supporting a role for liver monocytes and/or 
macrophages in the promotion of liver fibrosis reduction.   
 
Abstract word count:  181   Keywords: C1-3, drug targeting, gliotoxin, stellate, 
scAb, MMP-13. 
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1.  Introduction 
Liver fibrosis is a common outcome in patients with chronic liver damage of any 
cause [1].  It is associated with the activity of liver-resident fibroblasts, derived from 
the trans-differentiation of hepatic stellate cells (HSCs) to myofibroblast-like cells or 
the proliferation of portal fibroblasts [1].  The fibrogenic response is a component of 
the inflammation that occurs in response to hepatocyte necrosis, with liver 
myofibroblasts likely functioning to re-model the extracellular matrix prior to tissue 
regeneration [1]. 
 Most clinical liver disease is associated with chronic liver injuries and 
excessive inflammation. [1].  Liver myofibroblasts generate scarring within the tissue 
that ultimately leads to cirrhosis.  Under these conditions, the liver is unable to 
regenerate and the only treatment available at present is liver transplantation [1].  This 
laboratory [2,3] and others [4-8] have shown that a stimulation of pro-fibrogenic liver 
myofibroblast apoptosis reduces scarring in recovery animal models of liver fibrosis.  
These experiments suggest that reductions in the numbers of liver myofibroblasts in a 
fibrotic liver may be an effective therapeutic approach to chronic liver disease.  
However, it is now clear that a complex relationship exists between various liver cell 
types in the diseased liver.  The initial switch that triggers a fibrogenic response in 
liver myofibroblasts has not been unequivocally identified but there is good evidence 
to suspect that liver-resident macrophages (Kupffer cells) are its (major) source [1].  
Further, many of the pro-inflammatory cytokines produced by Kupffer cells promote 
liver myofibroblast fibrogenic activity, most notably interleukin 6, TNF-α  and TGF-β 
[9-13].  The prominent role of Kupffer cells in fibrogenesis was elegantly 
demonstrated by Duffield et al in which fibrosis was significantly reduced in a mouse 
model of disease when Kupffer cells were depleted from the liver [14].  Surprisingly 
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however, Kupffer depletion also inhibited the normal reversal of fibrosis that can 
occur prior to cirrhosis when liver damage was halted [14].  Therefore, an effective 
anti-fibrotic therapy reliant on the stimulation of apoptosis may likely need to be 
specifically targeted to liver myofibroblasts for optimum efficacy. 
 Synaptophysin is a membrane protein present in a restricted number of cell 
types such as neural cells.  It is thought to function in the release and/or uptake of 
neurotransmitters [15].  In the liver, synaptophysin expression is reported to be 
restricted to HSC-derived myofibroblasts (myofibroblasts express a number of genes 
associated with neural tissue) [14-19].  Synaptophysin's external cellular location and 
cycling to intracellular location(s) make it a potential site for targeting liver 
myofibroblasts with therapeutics.  Recombinant human monoclonal single chain 
antibodies (scAbs) were therefore generated to a conserved peptide sequence present 
in an extracellular domain of synaptophysin [20]. 
 In this study we show that the C1-3 scAb does not cross the blood brain barrier 
and targets liver myofibroblasts in vivo in a mouse model of liver fibrosis.  In 
addition, gliotoxin - a compound shown to stimulate apoptotic-resistant fibrogenic 
human HSC apoptosis in vitro [37], when chemically conjugated to C1-3, 
significantly reduced the numbers of liver myofibroblasts present in the fibrotic 
disease model without affecting Kupffer cell numbers.  The effects of the C1-3-
gliotoxin conjugate were compared to the effects of free gliotoxin and a control scAb-
gliotoxin conjugate (CSBD9, a scAb raised to microcystin [21], which should not 
bind to the surface of liver cells).  
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2. Materials and methods 
 
2.1.  Recombinant scAb expression and conjugation. 
 
The polyhistidine tagged recombinant scAbs - C1-3 (to synaptophysin) and 
CSBD9 (to microcystin-LR [21] and used as a control in these studies) were 
expressed in E. coli and purified by nickel chromatography and gel filtration 
essentially as previously described [20,21].  Endotoxin was removed from 
preparations using Q Maxi H columns (Sartorius Vivascience, Epsom, UK) and all 
preparations were tested (< 0.2 EU/ml) by Lonza Biologics (Slough, UK) prior to use 
in vivo.  Purified scAbs were labelled with FITC as previously outlined [20].  
Gliotoxin was conjugated to scAbs essentially as outlined [22] – see also 
supplementary Fig. 1.  Protein conjugates were analysed by an Applied Biosystems 
Voyager DE-STR-MALDI-TOF mass spectrometer (Aberdeen Proteomics).  
Gliotoxin conjugation was further confirmed by Western blotting as outlined [23] 
using an antibody to gliotoxin supplied by Dr Sean Doyle (National University of 
Ireland, Maynooth, Ireland).  ScAb conjugates contained < 0.2 % gliotoxin in its free 
form (supplementary Fig. 2). 
 
 
2.2  In vitro functional tests of recombinant scAb conjugate activity. 
 
Antigen binding ELISA with peptide 2 (YPFRLHQVYFDAPSC sequence to 
which the C1-3 scAb binds) and peptide 1 (ATDPENIIKEMPMC, an unrelated 
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sequence also present within synaptophysin) as a control were performed using BSA-
peptide conjugates as outlined [20]. 
 
2.3  BIAcore. 
 
BSA conjugates with peptides 1 or peptide 2 were covalently immobilised to a 
CM5 sensor chip (GE Healthcare, Amersham, UK) and scAb binding kinetics 
determined as outlined [24]. 
 
  
2.4  HSC isolation and culture. 
 
Male adult mice (C57Bl6) were used in all studies and were purchased from 
Harlan.  Mouse HSCs were isolated from mechanically disrupted whole liver as 
outlined [26] and cultured as described [2,25].  The cells were sub-cultured by trypsin 
digestion and were used between passages 2 and 4. 
 
 
2.5  Western blotting. 
 
Western blotting was performed as outlined [26] using HRP-conjugated 
secondary antibodies and detection with ECL reagent (Amersham) and 
autoradiography.  Goat anti-human Cκ light chain was used to detect C1-3 scAb and 
was purchased from the Sigma Chemical Co. Poole, UK.  Mouse monoclonal 
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antibodies to α-smooth muscle actin and β-actin were from Sigma and Chemicon 
(Chandlers Ford, UK) respectively. 
 
2.6  CCl4 in vivo model of liver fibrosis and scAb treatment. 
 
Mice were administered CCl4 mixed 1:1 (v/v) with olive oil - 2ml/kg body 
weight by i.p injection - twice weekly for 8 weeks to generate liver fibrosis.  Control 
animals were administered olive oil alone (1ml/kg body weight).  Free gliotoxin was 
administered in DMSO at 60 µg / 100 g body weight (0.5 mg gliotoxin/ml), control 
animals received DMSO (120 µl / 100g body weight) alone.  All scAbs and scAb 
conjugates were prepared in phosphate buffered saline (PBS 137 mM NaCl, 2.7 mM 
KCl, 10 mM phosphate pH 7.4) and administered at 2 mg scAb / 100 g body weight 
(from a 1 mg/ml PBS stock by i.p. injection).  As scAb conjugates, mice received the 
equivalent of 60 µg gliotoxin / 100 g body weight.  At various timepoints, mice were 
anaesthetised using isoflurane and blood taken by cardiac puncture.  All animals were 
then killed by cervical dislocation and samples of various tissues snap-frozen in dry 
ice or fixed in 10 % formalin in PBS.  Blood was allowed to clot prior to 
centrifugation to obtain serum for analyses. 
 
 
2.7  Tissue analysis. 
 
Serum ALT levels, sirius red staining and α-smooth muscle actin 
immunostaining were performed as previously outlined [2].  The mouse monoclonal 
α-smooth muscle actin antibody was purchased from Sigma (Poole, UK), and sections 
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then developed using the mouse on mouse Vectastain system (Vector Labs, 
Peterborough, UK).  Immunostaining tissue for C1-3 scAb was undertaken using 
HRP-conjugated goat anti-human Cκ light chain antibody followed by DAB colour 
development.  Anti-F4/80 (for monocytic and Kupffer cells in formalin fixed tissue) 
and metalloproteinase-13 (MMP-13) antibodies were purchased from Abcam.  Frozen 
tissue was sectioned at a thickness of 6 µm in O.C.T. embedding compound.  In co-
localisation studies, sections were further incubated with Alexa Fluor 594-conjugated 
antibodies (either the anti-α-smooth muscle actin above or mouse anti- ED-1, note 
anti-ED-1 was more effective than anti-F4/80 in frozen sections).  Sections were then 
DAPI mounted and examined using a UV microscope. 
 
 
3. Results 
 
ScAb conjugation does not significantly affect antigen affinity and 
conjugate activity in vitro. 
C1-3 and CSBD9 ScAbs were conjugated with FITC or gliotoxin.  Figure 1A 
demonstrates that the mean molecular weight of the C1-3 scAb after conjugation with 
gliotoxin increased by an average of 1.5 kDa indicating that on average 3.5 molecules 
of gliotoxin had been conjugated to the C1-3 scAb protein (see supplementary Figure 
1).  Similar results were observed with the CSDB9 scAb (data not shown).  FITC 
conjugation generally resulted in the conjugation of 4-5 molecules of fluorescein per 
molecule of protein (data not shown).  Western blotting using an antibody raised to 
gliotoxin confirmed that gliotoxin had been conjugated to proteins (Figure 1B) and 
additional analysis confirmed that free gliotoxin did not remain within the 
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preparations – see supplementary Figure 2).  Figures 1C and D demonstrate that 
despite conjugation with gliotoxin or FITC, C1-3 scAb retained its affinity for peptide 
2 (the sequence originally used during panning for phage expressing antibody for 
synaptophysin [20]) with no affinity for peptide 1 or the BSA carrier protein.  CSBD9 
scAb and its conjugates did not bind to peptide 1 or 2 sequences (Figure 1D) although 
affinity for its antigen - microcystin – was not affected (Figure 1E).  Figure 1F 
demonstrates that the gliotoxin conjugate retained almost identical kinetics for peptide 
2 binding, with C1-3 and C1-3-GT showing <10-7 M affinity (Table 1). 
 The isolation and culture of HSCs on plastic in serum-containing medium 
results in trans-differentiation to a myofibroblast-like cell with phenotypically similar 
characteristics to the cells present in fibrotic liver [1].  Figure 2A demonstrates that 
the expression of the C1-3 scAb antigen was markedly increased in human HSC-
derived myofibroblasts and was present in the human stellate-like cell line LX-2 [24].  
The antigen was also present in mouse myofibroblasts from C57Bl6 mice.  C1-3-
FITC scAb readily interacted with a surface antigen on mouse myofibroblasts under 
native conditions (Figure 2B).  Confocal microscopy shows that the C1-3 scAb bound 
to the plasma membrane of cells but also that there was intracellular binding of a 
lower intensity (Figure 2B).   Gliotoxin stimulates a rapid apoptosis of rat and human 
HSC-derived myofibroblasts [2,23].  Addition of C1-3-GT or free gliotoxin to mouse 
HSC-derived myofibroblasts in vitro resulted in cell death whereas the C1-3 scAb 
protein alone was not toxic (Figure 2C and 2D).  CSBD9 and CSBD9-GT were not 
toxic to mouse myofibroblasts (Figure 2D) indicating that C1-3-GT-derived gliotoxin 
uptake was dependent on C1-3 interaction with its antigen.  The abilities of C1-3 scAb 
to interact with its antigen and gliotoxin to stimulate cell death were therefore not lost 
by their conjugation.  
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The C1-3 scAb targets mouse HSCs in vivo. 
To establish whether the C1-3 scAb is able to target liver myofibroblast in 
vivo, mice were administered CCl4 for 8 weeks to generate fibrosis (Figure 3A).  A 
comparison of indices of liver damage and fibrosis indicates that animals administered 
CCl4 had significant liver damage (elevated serum ALT) and liver myofibroblast 
proliferation, see Figure 3B.  Figure 3C shows that C1-3 scAb entered the systemic 
circulation within 20 minutes of i.p. administration and had a half-life of 
approximately 2 hours.  Analyses of tissue homogenates (liver, kidney, brain, skeletal 
muscle and adipose tissue) indicates that C1-3 scAb was detectable in kidney 
transiently (at 20 minutes) and for between 2 – 6 hours in the liver (Figure 3C).  All 
other tissues were negative for C1-3 at all time points (data not shown).  
Immunohistochemical examination of tissues with an antibody to the Cκ light chain 
tag present in the scAb indicates that C1-3 was present in the livers of mice with 
fibrosis but not control mice (Figure 3D).  C1-3 was not detected in any other tissue 
by this method, including the kidney and brain (Figure 3E).  The appearance of C1-3 
in kidney extracts may therefore have been due to free scAb within blood that 
contaminated tissue homogenates to varying degrees.  C1-3 scAb targeted cells within 
the scar of fibrotic livers (Figure 3D) and was not present within the parenchyma.  
Cell counts for C1-3-positive cells in randomly selected central veins indicate that the 
number of positive cells increased after administration of scAb to a peak at 6 hours 
and subsequently fell to a lower but significant level by 24 hours (Figure 3F). 
Minimal evidence for C1-3 immunoreactivity was observed in fibrotic liver 
tissue cut from archived standard formalin-fixed/paraffin-embedded tissue (data not 
shown), suggesting that the antigenic site for the C1-3 scAb is destroyed by formalin 
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fixation.  In contrast, C1-3 scAb readily bound to frozen sections of (native) fibrotic 
liver tissue (not shown).  Staining liver sections from mice that had previously been 
injected with C1-3-FITC scAb indicates that the C1-3-FITC bound to cells within the 
fibrotic liver but not control liver (Figure 4A).  Figure 4B confirms that the C1-3-
FITC antibody co-localised with α-sma positive cells (Figure 4B) but not ED-1 
positive monocytes and/or macrophages (Figure 4C).  These data suggest therefore 
that the C1-3 scAb was bound specifically to liver myofibroblasts in vivo. 
 
Gliotoxin-dependent reversal of fibrosis in vivo is significantly enhanced 
through its conjugation to the C1-3 scAbs. 
Previous work has demonstrated that the fungal metabolite gliotoxin is a 
potent stimulator of myofibroblast apoptosis in vitro through its dual action of an 
inhibition of NF-κB and promotor of mitochondrial membrane permeability [2,23].  
Gliotoxin administration reversed fibrosis in vivo in recovery rat models [2,4].  
However, gliotoxin also stimulates the apoptosis/necrosis of Kupffer cells [27,28] 
which have been shown to be promote more effective fibrosis reversal [14].  Further, 
under inflammatory conditions, hepatocytes may be more susceptible to cell death if 
NF-κB is inhibited [2,23].  
We hypothesised that fibrosis reversal with gliotoxin would be more effective 
if myofibroblast apoptosis was specifically targeted.  To test this hypothesis, free 
gliotoxin was administered to mice with liver fibrosis (Figure 5A) and its effects 
within the liver compared to an equivalent dose of gliotoxin as a conjugate with C1-3 
(C1-3-GT) or the control scAb CSBD9 (CSBD9-GT).  A pilot experiment showed 
that free gliotoxin was toxic to CCl4-treated mice at 3 mg/kg body weight (the dose 
which most effectively reversed fibrosis in a rat recovery model [2]).  Accordingly, all 
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mice received a reduced 0.6 mg gliotoxin/kg body weight as either a free or a scAb 
conjugate form.   
Figure 5B demonstrates that free gliotoxin increased by two-fold non 
parenchymal cell apoptosis and significantly reduced by 30% the number of α-sma 
positive cells in the liver, essentially as observed previously in a rat model of liver 
fibrosis recovery [2].  Figure 5C shows that C1-3-GT was more effective in that non 
parenchymal cell apoptosis was increased 5-fold and the number of myofibroblasts 
present in the liver was significantly reduced by 60%.  The lack of effect of the 
CSBD9-GT scAb confirms that the C1-3 scAb specifically directs gliotoxin to 
myofibroblasts in vivo.  Figure 6A and B confirm that free gliotoxin treatment 
significantly reduced the number of Kupffer cells and MMP-13 positive cells present 
in the liver, and fibrosis severity was not markedly affected by gliotoxin in the 
sustained model employed here.  In contrast, C1-3-GT had no effects on the number 
of Kupffer cells present in the liver (Figure 6C), the levels of MMP-13 were 
maintained (Figure 6D) and fibrosis severity was significantly reduced (Figure 6D).  
Taken together, these data therefore suggest that the C1-3 scAb directs gliotoxin away 
from Kupffer cells, promotes increased myofibroblast apoptosis and reduces fibrosis.. 
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4. Discussion 
 
There are currently no treatments indicated for liver fibrosis [29].  In animal 
models of reversible fibrosis where the liver damaging agent is withdrawn (i.e. 
recovery), fibrosis resolution is accompanied by the apoptosis of liver myofibroblasts 
[30].  Previous work demonstrated – with free gliotoxin – that fibrosis resolution in 
rats was accelerated by stimulating the apoptosis of myofibroblasts [2,4].  In these 
studies, there was evidence in liver sections for an increase in the apoptosis of other 
cell types in response to gliotoxin although proportionately significantly less 
extensive than observed with myofibroblasts [2].  Since the presence of Kupffer cells 
in the liver promotes the accumulation of fibrosis and the resolution in recovery [14], 
a potential unwanted side-effect of an anti-fibrogenic that mediates myofibroblast 
apoptosis, could be the stimulation of Kupffer cell apoptosis in recovery.  Recent data 
indicated that free gliotoxin stimulates the apoptosis and necrosis of Kupffer cells in 
vitro and in vivo [28,31].  Targeted myofibroblast apoptosis and its effects on liver 
fibrosis were therefore investigated. 
The selectivity of our targeting scAb for liver myofibroblasts was 
demonstrated using an in vivo mouse model in which fibrogenesis was ongoing 
(treatment with scAbs or free gliotoxin was followed by further liver damage with 
CCl4).  The effects of free gliotoxin and targeted gliotoxin on fibrosis were tested.  In 
agreement with others [28,31], free gliotoxin significantly reduced the number of 
Kupffer cells present within the liver.  However, C1-3-targeted gliotoxin had no 
effects on the numbers of Kupffer cells.  The targeted apoptosis of myofibroblasts 
resulted in a more effective reduction in the numbers of α-sma positive liver 
myofibroblasts and fibrosis severity.  These data therefore support the concept that 
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myofibroblast reduction reverses and reduces severity in animal models of fibrosis.  It 
has been postulated that Kupffer cell-derived MMP13 expression makes a major 
contribution to fibrosis catabolism [32] and this is supported by our experiments.  The 
specific removal of myofibroblasts, whilst retaining the presence of Kupffer cells, 
may account for the enhanced reduction of fibrosis in C1-3-GT treated mice 
compared to free gliotoxin treated mice. 
Whilst this paper provides data in support of the hypothesis that retaining 
Kupffer cells whilst reducing myofibroblasts is an effective approach to reducing 
fibrosis severity, there remain some questions that need to be addressed with regard to 
myofibroblast apoptosis and anti-fibrogenic therapies.  These include the need to test 
the theory in additional models of liver disease since the population of myofibroblasts 
that proliferate in response to various disease aetiologies may be different [33].  
Further, efficacy in models of severe liver disease needs to be tested.  Myofibroblast 
apoptosis results in a rapid reduction in fibrosis in the current models employed, 
suggesting that scar turnover may be continuous and relatively rapid.  Cirrhosis (or 
“irreversible” fibrosis) in which excessive scarring is considered un-degradable, may 
yet resolve if in reality, scar is directly associated with the numbers of myofibroblasts 
and their intrinsic fibrogenic potential.  The ability of C1-3-GT to reverse fibrosis in 
models in which fibrosis is believed to not fully resolve [34] needs to be examined. 
This laboratory originally used gliotoxin as a model compound for examining 
the role of myofibroblast apoptosis as a therapy for fibrosis because it is potent and 
rapidly effective at killing myofibroblasts in vitro and in vivo [2,23].  Gliotoxin is an 
NF-κB inhibitor [35,36] but interestingly, was the only effective compound - in a 
range of NF-κB inhibitors – to stimulate the apoptosis of highly fibrogenic (passaged) 
human myofibroblasts in vitro [37].  It is likely that its efficacy is associated with both 
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an inhibition of NF-κB and a direct interaction with mitochondrial permeability [23].  
In view of the potential resistance of human myofibroblasts to apoptosis in cirrhosis, 
effective targeting of gliotoxin to myofibroblasts using the C1-3 scAb or similar 
targeting agent should be considered as a potential treatment for severe 
fibrosis/cirrhosis in patients followed by milder anti-fibrogenics which inhibit 
myofibroblast proliferation and/or fibrogenicity [25]. 
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7. Figure legends. 
Figure 1.  ScAb conjugation and antigen selectivity. 
 A, MALDI-TOF for purified C1-3 scAb (left panel) and C1-3-GT (right panel). B, 
Detection of covalently-bound gliotoxin in C1-3 or bovine serum albumin (BSA) 
prior to and after the conjugation procedure outlined in the Methods section.  C1-3-
SATA and BSA-SATA, proteins activated with conjugation agent prior to addition of 
activated gliotoxin, demonstrating selectivity of the antibody for gliotoxin (5 µg/lane).  
Predicted monomer protein-gliotoxin conjugates are indicated by arrows (additional 
higher molecular weight bands with C1-3 are likely to be multimers).  C, typical 
antigen binding ELISA (mean ± standard deviation 3 separate determinations) 
demonstrating selectivity of C1-3 scAb for BSA-peptide 2 versus BSA-peptide 1 and 
employed in D to show that scAb conjugation does not affect scAb binding to BSA-
peptide 2 for C1-3 or the control scAb CSBD9 (100 µg scAb/ml) or E, CSBD9 scAb 
binding to its microcystin antigen (100 µg scAb/ml).  F, typical BIAcore association 
and dissociation data for C1-3 and C1-3-GT scAbs employed in this study (see also 
Table 1). 
 
Figure 2.  Conjugation does not affect scAb binding to human and C57Bl6 mouse 
myofibroblasts or drug activity in vitro. 
A, Western blot for the presence of C1-3 antigen using the C1-3 scAb, α-smooth 
muscle actin and total actin.  Each lane contains 10 µg cell protein/lane, data typical 
of 3 separate experiments.  B, Left panels - immunofluorescence with unlabelled C1-3 
or C1-3-FITC in mouse myofibroblasts.  The indicated scAbs (10 µg/ml) were 
incubated with cells in culture media for 1 hour.  The cells were then washed several 
times with HEPES/HBSS [23] prior to examination.  All views taken under the same 
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lighting and exposure conditions.  Right panel, mouse myofibroblasts sub-cultured 
onto glass coverslips were washed in PBS, fixed (10 minutes in ice-cooled methanol 
followed by 10 minutes in 2% w/v formaldehyde / 0.2% w/v glutaraldehyde in PBS, 
pH 7.4) washed in PBS and then incubated with C1-3-FITC for 1 hour at rtp.  The 
cells were then washed in PBS and mounted in Vectasheild containing propidium 
iodide prior to analysis by confocal microscopy.  Green, C1-3-FITC; red, nucleus 
DNA.  Data typical of 5 separate experiments.  C, timecourse for the effects of free 
gliotoxin or C1-3-GT on mouse myofibroblast sub-stratum adherence in vitro.  
Culture-activated cells were sub-cultured into 24 well plates in 300 µl medium and 
treated with either free gliotoxin added from a 1000-fold molar concentrated stock in 
DMSO vehicle (total 450 pmoles/well); 4.5 µg C1-3 / well or 4.5 µg C1-3-GT scAb 
(to give approx. 450 pmoles gliotoxin /well for conjugated scAb).  Data are the mean 
and standard deviation of 3 separate preparations.  D, mouse myofibroblast 
attachment after 12 hours after incubation with the indicated scAb: GT, gliotoxin.  
Data are the mean and standard deviation of 10 randomly selected fields from the 
same experiment, typical of 3 separate experiments.  Significantly different (two 
tailed) using the Students T test from *DMSO control or ¶C1-3 scAb (P > 95%). 
 
Figure 3.  The CCl4 model of liver fibrosis and the C1-3 targeting of liver scars 
after injection.  A, schematic diagram of study 1, to determine whether C1-3-FITC 
binds to myofibroblasts in the fibrotic liver.  B,  evidence for liver damage and 
myofibroblast proliferation in mice administered CCl4 – left, increases in serum 
alanine aminotransferase (ALT) activity, mean and standard deviation from 3 animals 
per group; right, α-smooth muscle positive myofibroblasts, data typical of 3 animals 
24 hours after injection with C1-3-FITC or PBS.  C, Western blot for C1-3-FITC 
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scAb in serum prepared via cardiac bleed (10 µg/lane), liver (10 µg/lane) and kidney 
(10 µg/lane) at the time points indicated.  C1-3-FITC, purified standard (1 µg/lane).  
Tissue sections from control or fibrotic liver (6 h post injection), D, or brain and 
kidney (6 h post injection) , E, immunostained for C1-3-FITC via anti-human Cκ light 
chain tag.  Right panels are magnification of box outlined on corresponding left panel.  
Positive staining is brown.  F, blind scoring (10 fields/animal and 3 animals / time 
point) of C1-3-FITC positive cells in randomly selected centrilobular regions from 
fibrotic mice at the indicated time after administration of C1-3-FITC.  All data in D-E 
typical of at least 3 animals per time point. 
 
Figure 4.  The C1-3-FITC scAb targets liver myofibroblasts in fibrotic mouse 
liver. 
A. control and fibrotic liver sections from mice 6 hours after injection with C1-3 or 
C1-3-FITC scAbs.  Liver was snap-frozen and sections were mounted with DAPI 
Vectastain (stains nuclei blue) followed by analysis by fluorescence microscopy.  
Fibrotic liver sections from mice 6 hours after injection with C1-3-FITC scAb then 
incubated with anti-α-sma-AF-594 antibody (red) (B) or anti-ED-1-AF-594 antibody 
(red) (C), coverslipped with DAPI-containing Vectashield and analysed by confocal 
microscopy.  Typical results shown. 
 
Figure 5.  C1-3-GT scAb targets myofibroblasts and has greater efficacy over 
free gliotoxin to stimulate myofibroblast apoptosis in mouse liver in vivo. 
A, schematic diagram of study 2, to determine whether free gliotoxin or scAb-GT 
conjugate administration modulates liver fibrosis.  B, Representative immunostaining 
for α-smooth muscle actin in liver sections (left) from mice treated with gliotoxin 
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dissolved in DMSO (GT) or DMSO alone.  Quantitative analysis for non parenchymal 
active caspase 3 (typical view, inset) and α-sma positive cells - #Significantly different 
(two tailed) versus DMSO.  C, Representative immunostaining for α-smooth muscle 
actin in liver sections (upper panel) from mice treated with scAb and scAb-conjugates 
(dissolved in PBS) or PBS alone.    Quantitative analysis for non parenchymal active 
caspase 3 and α-sma positive cells.  Significantly different (two tailed) versus $PBS or 
*C1-3 treated groups.  Note, administration of various treatments did not affect the 
levels of liver damage as determined histologically (data not included) or from serum 
levels of ALT (supplementary Figure 3).  All data are the mean and standard deviation 
from at least 5 animals / treatment group with typical views presented and data tested 
for statistical significance using the Students T test (P > 95%).   
 
Figure 6.  Conjugation of gliotoxin to C1-3 scAb abrogates the loss of Kuppfer 
cells and enhances reductions in liver fibrosis. 
A,  Typical liver sections from animals treated with free gliotoxin dissolved in DMSO 
(GT) or DMSO only and immunostained for F4/80 for the detection of Kupffer cells 
(brown) – right upper panel is a high magnification view (K, Kupffer; H, hepatocyte).  
Bargraph, quantitative analysis for F4/80 positive cells B, Liver sections 
immunostained for MMP-13 and quantitation of the number of MMP-13 positive cells 
(upper panels) or stained with sirius red (lower panels).  Right lower, quantitative 
analysis for fibrosis severity in sirius red stained sections [26].  C, Typical liver 
sections from animals treated with scAb and scAb-conjugates (dissolved in PBS) or 
PBS alone and immunostained for F4/80 for the detection of Kupffer cells (brown).  
Bargraph, quantitative analysis for F4/80 positive cells.   D, Liver sections 
immunostained for MMP-13 (upper panels) or stained with sirius red (lower left 
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panels).  Right lower, quantitative analysis for fibrosis severity in sirius red stained 
sections [26].  Quantitation were made from 10 randomly selected fields per animal 
with at least 5 animals per group.  #Significantly different (two tailed) number of 
positive cells versus DMSO.  The mean and standard deviation sirius red score for 
each group is indicated with a horizontal and vertical line respectively.  *Significantly 
different (two tailed) severity versus C1-3 treated group using the Students T test (P > 
95%).   
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